NCT07224698

Inhaled Cannabis for Treatment of PTSD

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 320 (estimated)
• Sponsor: Multidisciplinary Association for Psychedelic Studies · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

Conditions

• Post Traumatic Stress Disorder PTSD

Interventions

Type	Name	Description
DRUG	High THC Cannabis	dried flower of the Cannabis sativa or indica plant with high (18-22%) THC content
DRUG	Placebo cannabis	Placebo contains \<1% THC

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-06-30
• Completion: 2027-11-30
• First posted: 2025-11-05
• Last updated: 2025-12-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study